Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MenABCWY 3rd Dose in Adolescents
NCT02285777Phase 2Completed
- Sponsor
- GSK
- Start
- Dec 2014
- Primary completion
- Mar 2015
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, double-blind trial of Meningococcal ABCYW vaccine in meningococcal disease (2 arms), sponsored by GSK. Primary endpoint: Percentages of Subjects Without Bactericidal Activity at 1:4 Dilution Against Each US N. Meningitidis Serogroup B Strain at Month 7. Started Dec 2014; status: completed.
02
Drugs
Meningococcal ABCYW vaccine
03
Conditions
meningococcal disease
Beyond the preview
Go deeper on NCT02285777.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02285777.